PEAL Capital Group

PEAL Capital Group is a Europe-based private equity firm specializing in the longevity and hormones sector, investing across Western Europe, the UK, and North America. The firm focuses on taking controlling or influential minority positions in mature lower-mid-cap businesses, providing hands-on operational and financial support from acquisition through exit. With over 65 years of combined industry expertise, PEAL Capital has sourced and managed 58 direct investments, achieving an average multiple on cost of 2.27x.

The firm's investment strategy centers on delivering strong, risk-adjusted returns by investing in secondary direct opportunities where their operational expertise and strategic oversight can unlock hidden value and accelerate growth. PEAL Capital emphasizes disciplined execution, full alignment with management teams, and long-term, sustainable growth. Their values include integrity, transparency, and building lasting partnerships.

PEAL Capital's approach involves sourcing undervalued assets through their executive network, medical panel, and family office relationships, conducting in-depth due diligence, and providing active management through board positions and interim C-suite appointments. They collaborate with management teams to shape long-term strategies, align incentives, and monitor key performance metrics, planning and executing disciplined exits to deliver shorter holding periods and strong risk-adjusted returns for investors. The firm's focus on the longevity and hormone sectors allows them to bring unique insight and value to a fast-growing healthcare market.